Adage Capital Partners’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,766,070
| Closed | -$180M | – | 963 |
|
|
2023
Q2 | $180M | Buy |
1,766,070
+1,296,452
| +276% | +$132M | 0.39% | 53 |
|
|
2023
Q1 | $42.7M | Sell |
469,618
-836,235
| -64% | -$76M | 0.1% | 251 |
|
|
2022
Q4 | $49.6M | Buy |
1,305,853
+1,065,829
| +444% | +$40.5M | 0.12% | 209 |
|
|
2022
Q3 | $6.03M | Sell |
240,024
-784,976
| -77% | -$19.7M | 0.02% | 750 |
|
|
2022
Q2 | $31.2M | Buy |
+1,025,000
| New | +$31.2M | 0.07% | 290 |
|
|
2021
Q4 | – | Sell |
-17,000
| Closed | -$1.71M | – | 1123 |
|
|
2021
Q3 | $1.71M | Buy |
+17,000
| New | +$1.71M | ﹤0.01% | 900 |
|
|
2020
Q2 | – | Sell |
-80,000
| Closed | -$11.5M | – | 809 |
|
|
2020
Q1 | $11.5M | Sell |
80,000
-33,000
| -29% | -$4.76M | 0.03% | 437 |
|
|
2019
Q4 | $23.1M | Buy |
113,000
+18,000
| +19% | +$3.68M | 0.06% | 362 |
|
|
2019
Q3 | $7.63M | Buy |
95,000
+50,000
| +111% | +$4.01M | 0.02% | 571 |
|
|
2019
Q2 | $4.25M | Buy |
+45,000
| New | +$4.25M | 0.01% | 631 |
|